Aldeyra Therapeutics

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aldeyra Therapeutics reports positive milestones and financial stability in Q4 2022

Aldeyra Therapeutics showcased positive performance in key milestones, financial stability, and progress in clinical studies, positioning the company for future growth.
Despite challenges in managing expenses and meeting enrollment deadlines, Aldeyra's strengths in its pipeline and financial position offer opportunities for success.
The upcoming year holds promise for Aldeyra with novel therapies addressing unmet medical needs and significant milestones expected in key trials.
Overall, Aldeyra's focus on advancing treatments for ocular and systemic conditions underscores its commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2020 Results - Earnings Call Transcript

Aldeyra (ALDX) reports narrower-than-expected loss in the second quarter of 2020.

Aldeyra's (ALDX) Q2 Earnings Beat Estimates, Pipeline in Focus

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update

Aldeyra's (ALDX) pipeline progress will be in focus when it reports Q2 results later in the week.

Aldeyra (ALDX) to Report Q2 Earnings: What's in the Offing?

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second-Quarter 2020 Financial Results and Corporate Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced block sales of an aggregate of 4,580,361 shares of common stock to Perceptive Advisors, LLC and Avidity Partners Management LP, two leading healthcare-focused investment funds, under Aldeyra’s previously announced at-the-market offering program. The share

Aldeyra Therapeutics Announces Stock Sales to Perceptive Advisors and Avidity Partners

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior and posterior ocular disease as part of the Ophthalmology Innovation Summit’s Virtual Public Company Showcase on Thursday, July 16, 2020. Dr. Brady’s presentation is scheduled for 1:40 to 1:50 p.m. ET. As part of the Showcase, Dr. Brady also will participate in the O

Aldeyra Therapeutics to Present at the OIS Virtual Public Company Showcase on July 16, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced development plans to support a New Drug Application (NDA) for the novel investigational reactive aldehyde species (RASP) inhibitor reproxalap in dry eye disease. Based on U.S. Food and Drug Administration (FDA) meeting minutes,

Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease

Aldeyra Therapeutics, Inc. (ALDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Strong Buy Stock

AbbVie

Kezar Life Sciences Inc

Aldeyra's Reproxalap Progress And Other News: The Good, Bad And Ugly Of Biopharma

Aldeyra Therapeutics' (ALDX) CEO Todd Brady on COVID-19 Development Update Conference Call - Transcript

Shares of Kindred Biosciences and Vaxart popped Wednesday after the drugmakers inked a manufacturing deal for a coronavirus vaccine tablet. Aldeyra is also planning to test a treatment.

Covid-19 Report: The Next Remdesivir? Aldeyra Therapeutics Is Working On It

Aldeyra (ALDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How Aldeyra (ALDX) Stock Stands Out in a Strong Industry

Aldeyra Therapeutics Inc (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aldeyra Therapeutics Inc (ALDX) Upgraded to Strong Buy: Here's What You Should Know

As of late, it has definitely been a great time to be an investor in Aldeyra Therapeutics.

Aldeyra's Shares March Higher, Can It Continue?

Aldeyra Therapeutics, Inc.'s (ALDX) CEO Dr.

Aldeyra Therapeutics, Inc. (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Aldeyra Therapeutics, Inc. (ALDX) a New Buy Stock

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q4 2019 Results - Earnings Call Transcript

Aldeyra Therapeutics Inc. shares ALDX, -6.14% rose more than 13% in premarket trade Tuesday before surrendering their gains, after the biotech reported positive results in the first part of a late-stage trial of a treatment for dry eye disease.

Aldeyra Therapeutics announces positive early  results in trial of dry eye disease treatment

Aldeyra Therapeutics Continues To Make Progress In Big Potential Markets Despite Stock Weakness

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2019 Results - Earnings Call Transcript

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2019 Results - Earnings Call Transcript

Shares of Aldeyra Therapeutics Inc., a thinly traded micro-cap biotech, plummeted Tuesday morning.

No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails

Aldeyra Therapeutics Inc. shares  were down 29% in premarket trade Tuesday, after the company said a trial of a treatment for uveitis, or inflammation of the eye, failed to meet its main goals.

Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals

Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q1 2019 Results - Earnings Call Transcript

News for Aldeyra Therapeutics Stock (ALDX)